Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer
Carrie C. Lubitz(Harvard University), Elizabeth G. Grubbs(The University of Texas MD Anderson Cancer Center), Tiannan Zhan(Massachusetts General Hospital), Julie Ann Sosa(Golden Gate University), R. Michael Tuttle(Memorial Sloan Kettering Cancer Center), Mara Y. Roth(University of Washington), Asmae Toumi(Massachusetts General Hospital), Colleen M. Kiernan(Vanderbilt University Medical Center)
Cited by 14
Related Papers
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
|Thyroid|2009|6.7k
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma
|JAMA Oncology|2016|1.4k
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
|New England Journal of Medicine|2013|825
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
|Journal of Clinical Oncology|2010|517
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|514